Cardiovascular risks with azithromycin

New England Journal of Medicine

Volumn 369, Issue 6, 2013, Pages 580-

  Brass, Eric P ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT; PENICILLIN V;

ANTIBIOTIC THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DEATH; DRUG SAFETY; DRUG USE; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; FEMALE; MALE; MORTALITY; NOTE; SUDDEN CARDIAC DEATH;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; MALE; PENICILLIN V;

EID: 84881223537     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1306999     Document Type: Letter

References (2)

1. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 2006;79:165-72.
2. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med 2008;359:1400-2.